Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.

摘要: BACKGROUND Chronic hepatitis C (CHC) virus infection in patients with cirrhosis is difficult to treat. There limited data on the outcome of treatment for genotype 3 HCV cirrhosis. AIMS To determine sustained virological response (SVR) and its predictive factors due treated pegylated interferon ribavirin (RBV). METHODS Consecutive compensated positive RNA peg-IFN RBV our Gastroenterology Clinics during November 2005 December 2006 were included this study. Cirrhosis was diagnosed basis liver biopsy and/or biochemical testing ultrasound abdomen. Primary end point SVR. RESULTS Of 66 patients, 32 (48.5%) male. The mean age 46.2 +/- 10.1 years; there 61 (92.4%) Child's A followed by 5 (7.6%) B type. 33 (50%) received alfa-2a (180 microg/wk) alfa 2b (1 microg/kg/week) ribavirin. EVR achieved 44 (66.7%), ETR 46 (69.7%); overall SVR 38 (57.6%) patients. Factors (p value = 0.03), naive status 0.04) < 0.001). Five unable complete side effects or cytopenias. CONCLUSIONS Treatment 3, cirrhosis, effective well tolerated.